TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03606954

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination topical corticosteroid
Description: Comparison of a vasoconstriction index between the 2 study arms

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination topical corticosteroid
Description: Comparison of a vasoconstriction index between the 2 study arms
Study: NCT03561415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Universal Posaconazole Prophylaxis
Description: All patients assigned to this arm will start posaconazole between Day 4 and Day 14 post lung or heart-lung transplant for a minimum of 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-emptive Posaconazole Therapy
Description: Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease for 3 months.
Study: NCT00176592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaseron
Description: Betaseron 250 micrograms injected SQ every other day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone
Description: Copaxone 20 mg injected SQ every day (glatiramer acetate)
Study: NCT00884299

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet rich in antioxidants
Description: Dietary intervention based on diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients are advised by a physician and a specialist nurse during regular scheduled outpatient clinic visits to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the study period.
Study: NCT00973479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab
Description: Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate (MTX)
Description: Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate (MTX)
Description: Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
Study: NCT04332289

Intervention type: OTHER
Intervention: Heavy water experiment
Description: 3 times daily heavy water (deuterated-water) and mixed meal administration for one week

Intervention type: OTHER
Intervention: Heavy water experiment
Description: 3 times daily heavy water (deuterated-water) and mixed meal administration for one week
Study: NCT00771524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Description: Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
Study: NCT03991052

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: This system will recommend when patients need fluid or not and nurses will adjust vasopressor administration as usual (standard of care)
Study: NCT02578056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midurethral sling
Description: Anti-urinary incontinence procedure, in a prophylactic way.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genital prolapse surgery
Description: Surgical correction of genital prolapse

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Genital prolapse surgery
Description: Surgical correction of genital prolapse
Study: NCT03392649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym
Description: Tragus stimulation was done using the Parasym device.
Study: NCT02106494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APF530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APF530 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study: NCT03963115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine or normal saline
Description: epinephreine or normal saline coated syringe before drawing allergen for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrine or normal saline
Description: epinephreine or normal saline coated syringe before drawing allergen for injection.
Study: NCT01425879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01170806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy
Study: NCT02245789

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Description: Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and remifentanil anesthesia
Description: The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil anesthesia
Description: The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
Study: NCT04352751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: convalescent plasma
Description: * Plasmapheresis, 900 - 1000 mL each time.~* Standard apheresis plasma collection protocol using Haemonetics MCS+ intermittent blood flow system or Terumo Optia, Cobe-Spectra, Trima or Fresenius continuous flow system to be used.~* Isovolumic saline replacement should be done.~* Each donor can donate convalescent plasma again after an interval of every 2 weeks
Study: NCT03659305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-001
Description: Concentrate for preparation solution for infusion in ampules, 25 mg/mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Concentrate for preparation solution for infusion in ampules, 25 mg/mL
Study: NCT01028157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STARS: Sistas Talking About Real Solutions
Description: The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health & Nutrition
Description: Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
Study: NCT02679859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BNP guided medical therapy optimisation
Study: NCT01113632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.
Study: NCT03471533

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutraceutical: experimental product
Description: 84 days of consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 84 days of consumption
Study: NCT04291339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen technique
Description: High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mask ventilation technique
Description: Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
Study: NCT02578927

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GT+Ex
Description: In this session the volunteers ingested capsules with 2g of powder green tea before exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PL+Ex
Description: In this session the volunteers ingested capsules with 2g of placebo before exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea
Description: In this investigation the volunteers ingested capsules with 2g of powder green tea before the rest similar to the exercise time
Study: NCT03040635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Single oral doses of Risdiplam will be administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Single oral doses of Risdiplam will be administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Single oral doses of Risdiplam will be administered on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral doses of Risdiplam matching placebo will be administered on Day 1.
Study: NCT03330938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBI and Resilience
Description: A combination of CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring) + Resilience strengthening (Identifying resilient strengths and potentialities, plus Imagination and projection into the future).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral Intervention
Description: Only CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring).
Study: NCT00922883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Study: NCT01051128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prometra Programmable Implantable Pump System
Description: The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
Study: NCT02948491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Song that the mother sings to the child before birth, recording of the mother's voice.
Study: NCT02114879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Medical Rehabilitation
Description: Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Rehabilitation
Description: Daily PT/OT provided by therapists not trained in the treatment intervention.
Study: NCT02098109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XM02 Filgrastim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Study: NCT00496847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PERIOGEN
Description: Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta TCP alone
Description: Implantation of β-TCP (0.5 g) alone
Study: NCT01116232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.~In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: management of therapy complications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: peripheral blood stem cell transplantation
Study: NCT00500292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: once daily oral tablet two dose strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: once daily oral tablet two dose strengths

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
Description: intravenous infusion
Study: NCT01894789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Blinded administration of ticagrelor for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Blinded administration of ticagrelor for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Blinded administration of clopidogrel and placebo for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Blinded administration of clopidogrel and placebo for 10 days
Study: NCT03168152

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Microwave Ablation (MWA)
Description: MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
Study: NCT01894152

Intervention type: DEVICE
Intervention: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
Description: Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
Study: NCT02741700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gout Storytelling Video Intervention
Description: The investigators developed a storytelling intervention for African-Americans with gout, to address barriers to optimal gout management and provide cues for better disease management, which were narrated by several Veterans with gout. One of the veterans also presented a PowerPoint on gout and its management. The intervention was shown to the participants on a touchscreen computer or the desktop screen at the baseline study visit. Subsequently, they were provided with DVD with similar intervention to watch at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gout Storytelling Video Intervention
Description: The investigators developed a storytelling intervention for African-Americans with gout, to address barriers to optimal gout management and provide cues for better disease management, which were narrated by several Veterans with gout. One of the veterans also presented a PowerPoint on gout and its management. The intervention was shown to the participants on a touchscreen computer or the desktop screen at the baseline study visit. Subsequently, they were provided with DVD with similar intervention to watch at home.
Study: NCT02251951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)
Study: NCT02372851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pureit As+ Filter
Description: The Pureit As+ water filter has been developed to effectively remove arsenic (both arsenite and arsenate) from over 300 µg/L to less than 10 µg/L in addition to removing microbial contamination (Institution of Public Health Engineers, 2011). It has an end-of-life indicator and consumables that do not re-contaminate the environment when disposed (Institution of Public Health Engineers, 2011). The technology requires no electricity, but only the replacement of the battery after 1000 L of water filtered (approximately 100 days based on a family of five drinking 2 L/day).
Study: NCT03144882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin Pill
Description: Turmeric rhizome at first was washed and dried out in a warm and dry place for a week , then powdered rhizomes were encapsulated by Clinical Pharmacy Research Center of Shahid Beheshti University of Medical Sciences, using hard gelatin capsules. Also placebo capsules were made by the same center using Sorbitol. Curcumin level of turmeric was measured by HPTLC analysis for quantification of variability in content of curcumin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03234660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 0.9% normal saline continuous infusion